Calciphylaxis, or calcific uremic arteriolopathy, is a rare condition that manifests as subcutaneous vascular calcification and cutaneous necrosis (small blood vessels of the fat tissue and the skin). Some authors describe it as a syndrome of vascular calcification, thrombosis and skin necrosis.
On this page:
Epidemiology
It is seen most often in patients with end stage renal disease (usually on haemodialysis) although this is not an absolute requirement. There may be a greater female predilection.
Clinical presentation
The cutaneous lesions start with tender red areas developing into a livedoid pattern. Solitary or multiple indurated plaques and/or nodules are then seen. Patients may subsequently develop an eschar followed by frank ulceration, gangrene, or sepsis.
Patients may have palpable deposits of calcium, and bullae may be noted. The most consistent feature of calciphylaxis is pain. Extreme pain is noted when the skin around the ulcer is palpated.
Pathology
It is a complex disorder with a multifactorial etiology. The exact pathogenesis of calciphylaxis is unclear. Medial calcification and intimal fibrosis of the cutaneous arterioles combined with thrombotic occlusion leading to ischemic skin necrosis is seen in calciphylaxis.
Distribution
The lower extremities are the most common area to be involved, with legs being the most common site while the face and upper extremities are rarely involved.
Treatment and prognosis
There can be significant morbidity and mortality from the disease, most commonly resulting from septicemia due to impaired integrity of the epidermis and dermis.
More than 50 percent of patients die (most commonly from sepsis) within one year of being diagnosed.
History and etymology
The condition was first described in 1898 by Bryant and White although the term “calciphylaxis” was coined by Hans Selye in 1962.
Unable to process the form. Check for errors and try again.